Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085024001> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W2085024001 endingPage "21" @default.
- W2085024001 startingPage "12" @default.
- W2085024001 abstract "The efficacy and safety of pregabalin as adjunctive therapy for patients with partial epilepsy with or without secondary generalization has been established by four randomized, 12‐week, double‐blind, placebo‐controlled trials ( n = 1396) and four long‐term open‐label studies ( n = 1480). Patients in the three fixed‐dose trials were ≥12 years of age, had ≥6 partial seizures and no 4‐week seizure‐free period during the 8‐week baseline period. Seventy‐three per cent of patients were taking ≥2 concomitant antiepileptic drugs. Responder rates across the effective doses (150–600 mg/day) ranged from 14% to 51% and demonstrated a significant dose–response relationship. The most common adverse events were central nervous system related, generally mild or moderate, transient, and tended to be dose related. The fourth placebo‐controlled trial compared a fixed dose of pregabalin 600 mg/day with a flexible‐dose regimen (150–600 mg/day). Responder rates were greater for both the fixed dose (45.3%, P < 0.001) and flexible dose (31.3%, P < 0.001) when compared with placebo (11.0%). Compared with the fixed‐dose group, the flexible‐dose patients had a lower incidence of adverse events and study discontinuations. In long‐term open‐label trials, the efficacy of pregabalin was maintained with respect to 50% responder rates suggesting no obvious tolerance developing over 2 years. Seizure‐free rates were 8.9% and 5.8% for the last 6 months and 1 year of pregabalin treatment, respectively. Long‐term open‐label pregabalin treatment was well tolerated." @default.
- W2085024001 created "2016-06-24" @default.
- W2085024001 creator A5023594320 @default.
- W2085024001 date "2005-09-06" @default.
- W2085024001 modified "2023-10-13" @default.
- W2085024001 title "Defining success in clinical trials – profiling pregabalin, the newest AED" @default.
- W2085024001 cites W1974148982 @default.
- W2085024001 cites W1991467694 @default.
- W2085024001 cites W1998011222 @default.
- W2085024001 cites W2041426021 @default.
- W2085024001 cites W2049838912 @default.
- W2085024001 cites W2055427394 @default.
- W2085024001 cites W2059212626 @default.
- W2085024001 cites W2073587246 @default.
- W2085024001 cites W2076516150 @default.
- W2085024001 cites W2078797427 @default.
- W2085024001 cites W2090188920 @default.
- W2085024001 cites W2139910132 @default.
- W2085024001 cites W2170481173 @default.
- W2085024001 cites W4256651757 @default.
- W2085024001 doi "https://doi.org/10.1111/j.1468-1331.2005.01327.x" @default.
- W2085024001 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16144536" @default.
- W2085024001 hasPublicationYear "2005" @default.
- W2085024001 type Work @default.
- W2085024001 sameAs 2085024001 @default.
- W2085024001 citedByCount "29" @default.
- W2085024001 countsByYear W20850240012012 @default.
- W2085024001 countsByYear W20850240012013 @default.
- W2085024001 countsByYear W20850240012014 @default.
- W2085024001 countsByYear W20850240012015 @default.
- W2085024001 countsByYear W20850240012019 @default.
- W2085024001 crossrefType "journal-article" @default.
- W2085024001 hasAuthorship W2085024001A5023594320 @default.
- W2085024001 hasConcept C118552586 @default.
- W2085024001 hasConcept C126322002 @default.
- W2085024001 hasConcept C142724271 @default.
- W2085024001 hasConcept C168563851 @default.
- W2085024001 hasConcept C197934379 @default.
- W2085024001 hasConcept C204787440 @default.
- W2085024001 hasConcept C27081682 @default.
- W2085024001 hasConcept C2776468701 @default.
- W2085024001 hasConcept C2777803345 @default.
- W2085024001 hasConcept C2778186239 @default.
- W2085024001 hasConcept C2779384505 @default.
- W2085024001 hasConcept C2781413609 @default.
- W2085024001 hasConcept C3018162438 @default.
- W2085024001 hasConcept C42219234 @default.
- W2085024001 hasConcept C535046627 @default.
- W2085024001 hasConcept C71924100 @default.
- W2085024001 hasConceptScore W2085024001C118552586 @default.
- W2085024001 hasConceptScore W2085024001C126322002 @default.
- W2085024001 hasConceptScore W2085024001C142724271 @default.
- W2085024001 hasConceptScore W2085024001C168563851 @default.
- W2085024001 hasConceptScore W2085024001C197934379 @default.
- W2085024001 hasConceptScore W2085024001C204787440 @default.
- W2085024001 hasConceptScore W2085024001C27081682 @default.
- W2085024001 hasConceptScore W2085024001C2776468701 @default.
- W2085024001 hasConceptScore W2085024001C2777803345 @default.
- W2085024001 hasConceptScore W2085024001C2778186239 @default.
- W2085024001 hasConceptScore W2085024001C2779384505 @default.
- W2085024001 hasConceptScore W2085024001C2781413609 @default.
- W2085024001 hasConceptScore W2085024001C3018162438 @default.
- W2085024001 hasConceptScore W2085024001C42219234 @default.
- W2085024001 hasConceptScore W2085024001C535046627 @default.
- W2085024001 hasConceptScore W2085024001C71924100 @default.
- W2085024001 hasIssue "s4" @default.
- W2085024001 hasLocation W20850240011 @default.
- W2085024001 hasLocation W20850240012 @default.
- W2085024001 hasOpenAccess W2085024001 @default.
- W2085024001 hasPrimaryLocation W20850240011 @default.
- W2085024001 hasRelatedWork W1536206906 @default.
- W2085024001 hasRelatedWork W1971234504 @default.
- W2085024001 hasRelatedWork W1975953218 @default.
- W2085024001 hasRelatedWork W2073028005 @default.
- W2085024001 hasRelatedWork W2119629508 @default.
- W2085024001 hasRelatedWork W2324232611 @default.
- W2085024001 hasRelatedWork W2435907572 @default.
- W2085024001 hasRelatedWork W2801678777 @default.
- W2085024001 hasRelatedWork W4243356075 @default.
- W2085024001 hasRelatedWork W3167578198 @default.
- W2085024001 hasVolume "12" @default.
- W2085024001 isParatext "false" @default.
- W2085024001 isRetracted "false" @default.
- W2085024001 magId "2085024001" @default.
- W2085024001 workType "article" @default.